Learn if You Have a Claim Against Cordis Corporation

Adverse Reactions, Including Death, Associated with Cypher Heart Stent Kahn Gauthier Swick is investigating possible legal actions against Cordis Corporation on behalf of persons who have been injured by the company's Cypher coronary stent. On October 29, 2003, the federal Food and Drug Administration issued a warning that a significant number of adverse effects had been reported since the Cypher stent was approved on April 24. Both blood clotting and hypersensitivity reactions have been reported.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Have you undergone angioplasty with a Cypher stent to open clogged coronary arteries?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name
Age
Relationship
Surgery Information

Date of Surgery
Have you suffered a blood clot after your surgery?	Yes No
Have you suffered a hypersensitivity reaction after your surgery?	Yes No
Please describe any injuries that you associate with use of the Cypher coronary stent.
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Physician Corporation of America Stockholders Recover $10.2 Million

The parties have reached a tentative $10.2 million settlement of a class action filed against managed healthcare company Physician Corporation of America (Nasdaq: PCAM) and certain of its officers and directors by stockholders who purchased the company's common stock between March 31, 1996, and March 31, 1997, and still owned the stock on the latter date. To recover under the settlement, a completed proof of claim postmarked no later than December 22, 2003, must be mailed to the claims administrator.

MiniMed Stockholders Reach $1.25 Million Settlement in Aftermath of 2001 Acquisition by Medtronic

The parties have reached a tentative $1.25 million settlement in a class action filed against MiniMed, Inc., and certain of its officers and directors by stockholders who held the company's common stock as of July 16, 2001. Persons eligible to participate in the settlement must submit a proof of claim form postmarked no later than September 13, 2004.

Stockholders Claim Dura Pharmaceuticals Misled Market

A class action has been filed against Dura Pharmaceuticals, Inc. (formerly Nasdaq: DURA) and certain of its officers and directors by stockholders who purchased the company's common stock between April 15, 1997, and February 24, 1998.

IntraBiotics Pharmaceuticals Failed to Disclose Iseganan Failure

Several class actions have been filed against biopharmaceutical company IntraBiotics Pharmaceuticals, Inc., (Nasdaq:IBPI) and certain of its officers and directors by stockholders who purchased the company's common stock between September 5, 2003, and June 22, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Titan Pharmaceuticals Allegedly Overstated Prospects for Success of Proposed New Drug Iloperidone

A class action has been filed against biopharmaceutical company Titan Pharmaceuticals, Inc. (AMEX: TTP) and certain of its officers and directors by stockholders who purchased the company's common stock between December 1, 1999, and July 22, 2002. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Intermune to Pay $37 Million for Promotion of Actimmune Drug

InterMune Inc., a biopharmaceutical company based out of California, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF).